V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320002841 | 320001681 | 1.62 | 72.9 | Palliative (P) | 2015-05-23 | 2015-05-25 | Cetuximab + CISPLATIN + FLUOROURACIL | N | N | 320016824 | OXALIPLATIN + MDG |
| 320002842 | 320001682 | 1.64 | 71.6 | Neo-adjuvant (N) | 2017-02-17 | 2017-02-17 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 2 | N | 320016838 | CARBOPLATIN + PEMETREXED |
| 320002843 | 320001683 | 1.7 | 67.2 | Curative (C) | 2013-06-02 | 2013-06-18 | CARBOPLATIN + RT | 02 | Y | 320016840 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320002844 | 320001684 | 1.62 | 43 | Not known (9) | 2014-01-10 | 2014-01-10 | Trial Unspecified | 2 | N | 320016852 | CISPLATIN + GEMCITABINE |
| 320002845 | 320001685 | 1.67 | 45.4 | Adjuvant (A) | 2013-12-15 | 2013-12-16 | ICON8 TRIAL | N | N | 320016855 | IVA |
| 320002846 | 320001685 | null | 110 | Palliative (P) | 2017-01-10 | 2017-01-15 | Cetuximab 7 day (>Cycle 2) | N | N | 320016855 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 320002847 | 320001685 | 1.59 | 56 | Palliative (P) | 2016-01-29 | 2016-02-19 | Bevacizumab + CARBOPLATIN + PACLITAXEL | N | N | 320016855 | PEMBROLIZUMAB |
| 320002848 | 320001685 | 1.7 | null | Palliative (P) | 2016-05-29 | 2016-05-30 | CISPLATIN + DOCETAXEL + FLUOROURACIL | N | N | 320016855 | FLUOROURACIL + MITOMYCIN + RT |
| 320002849 | 320001686 | 0 | 58.7 | Neo-adjuvant (N) | 2016-01-25 | 2016-02-07 | Carboplatin + Doxorubicin | N | N | 320016883 | CETUXIMAB |
| 320002850 | 320001687 | 1.7 | 107.9 | Palliative (P) | 2017-01-26 | 2017-02-10 | Carboplatin + Etoposide iv&po | N | N | 320016894 | CAPECITABINE + CARBOPLATIN |
| 320002851 | 320001688 | null | 44.4 | Palliative (P) | 2016-12-09 | 2016-12-12 | FEC 60 or 75 | 02 | N | 320016902 | PEMBROLIZUMAB |
| 320002852 | 320001689 | 1.73 | 58.7 | Curative (C) | 2015-09-21 | 2015-09-25 | BCG Intravesical | Y | Y | 320016903 | CISPLATIN + GEMCITABINE |
| 320002853 | 320001689 | null | 92.85 | Not known (9) | 2015-04-28 | 2015-05-25 | Cisplatin+Gemcitabine (Days 1&8&15) | N | N | 320016903 | CISPLATIN + ETOPOSIDE |
| 320002854 | 320006294 | 1.76 | 51.4 | Palliative (P) | 2018-07-26 | 2018-07-26 | Cisplatin + Docetaxel +Fluorouracil | 02 | null | 320016924 | TRIAL |
| 320002855 | 320001690 | 1.62 | 85.8 | Palliative (P) | 2015-10-18 | 2015-11-04 | CETUXIMAB + RT | null | null | 320016927 | CARBOPLATIN + ETOPOSIDE |
| 320002856 | 320001691 | null | 88.9 | null | 2016-07-03 | 2016-07-29 | CARBOPLATIN + RT | null | null | 320016928 | CISPLATIN + GEMCITABINE |
| 320002857 | 320001692 | 1.63 | 56.9 | Palliative (P) | 2013-03-21 | 2013-03-31 | Trial Unspecified | null | N | 320016929 | BCG |
| 320002858 | 320001693 | 1.69 | 70 | Palliative (P) | 2017-03-13 | 2017-03-18 | CETUXIMAB + CISPLATIN + FU | 02 | N | 320016933 | EC |
| 320002859 | 320001694 | 1.66 | 54.6 | Curative (C) | 2013-11-01 | 2013-11-05 | FEC 100 | 02 | N | 320016934 | TCH |
| 320002860 | 320001695 | 1.83 | 62.2 | null | 2014-11-07 | 2014-11-10 | FLUOROURACIL + IRINOTECAN | N | N | 320016936 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320002861 | 320001696 | 1.7 | 106.2 | Palliative (P) | 2017-11-09 | 2017-11-10 | CARBOPLATIN + RT | 02 | N | 320016970 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320002862 | 320001697 | 1.56 | 54 | Curative (C) | 2017-02-20 | 2017-02-22 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 2 | Y | 320016977 | IRINOTECAN + MDG |
| 320002863 | 320001698 | 1.68 | 62 | Adjuvant (A) | 2016-09-10 | 2016-10-02 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 320016980 | CETUXIMAB + CISPLATIN + FU |
| 320002864 | 320001699 | 1.76 | 46.6 | Palliative (P) | null | 2016-06-15 | Cisplatin + Etoposide (3 day) | N | N | 320016988 | BEVACIZUMAB |
| 320002865 | 320001700 | null | 48.3 | Neo-adjuvant (N) | null | 2017-01-07 | BEVACIZUMAB + CARBO + PACLITAXEL | null | null | 320016992 | FEC + DOCETAXEL |
| 320002866 | 320004894 | 1.18 | 68 | Neo-adjuvant (N) | 2013-02-06 | 2013-02-18 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 320016993 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320002867 | 320001701 | 1.7 | 61.8 | Not known (9) | 2016-06-06 | 2016-06-06 | Capecitabine (14 days)+Carboplatin | 02 | null | 320016994 | CAPECITABINE + CETUXIMAB + CISPLATIN |
| 320002868 | 320001702 | 1.85 | 78.4 | Curative (C) | 2017-02-17 | 2017-02-18 | Carboplatin + Vinorelbine IV | Y | null | 320017000 | TRIAL |
| 320002869 | 320001703 | 1.65 | 83 | Not known (9) | 2014-02-17 | 2014-02-18 | Trial Unspecified | N | N | 320017003 | CARBOPLATIN + RT |
| 320002870 | 320001704 | 1.5 | 56.4 | Palliative (P) | 2015-02-17 | 2015-02-23 | Cisplatin + Fluorouracil + RT 5day | 02 | N | 320017004 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 320002871 | 320004895 | 1.72 | 76.1 | Curative (C) | 2017-03-14 | 2017-03-22 | Trial Unspecified | 02 | null | 320017011 | CAPECITABINE + MITOMYCIN |
| 320002872 | 320001705 | 1.64 | 52 | Curative (C) | 2013-12-18 | 2014-01-11 | IPILIMUMAB + NIVOLUMAB | null | N | 320017016 | PEMBROLIZUMAB |
| 320002873 | 320001706 | 1.76 | 102.4 | Palliative (P) | 2013-08-23 | 2013-09-05 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320017017 | ABIRATERONE |
| 320002874 | 320001707 | 1.61 | 54.2 | Adjuvant (A) | 2013-06-09 | 2013-06-09 | CARBOPLATIN + RT | 02 | N | 320017024 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320002875 | 320001707 | 1.91 | 65.1 | Palliative (P) | 2016-12-16 | 2016-12-16 | Cisplatin + Pemetrexed | 1 | N | 320017024 | CISPLATIN + GEMCITABINE |
| 320002876 | 320006295 | 1.58 | 66.5 | Curative (C) | 2014-12-07 | 2014-12-22 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 320017036 | TRIAL |
| 320002877 | 320001708 | 1.63 | 45 | Palliative (P) | 2013-02-16 | 2013-02-16 | STS Rhabdomyosarcoma RMS 2005 IVA | 2 | N | 320017040 | CETUXIMAB |
| 320002878 | 320001709 | 1.64 | 63 | Curative (C) | 2018-04-24 | 2018-04-24 | BCG Intravesical | 02 | N | 320017043 | CISPLATIN + VINORELBINE + RT |
| 320002879 | 320001709 | null | 46 | Palliative (P) | null | 2014-12-30 | Carboplatin + Etoposide iv&po | null | null | 320017043 | ECX |
| 320002880 | 320001710 | 1.92 | 74.9 | Palliative (P) | 2014-11-17 | 2014-11-23 | Ipilimumab | 02 | N | 320017055 | DOCETAXEL |
| 320002881 | 320001711 | null | 54 | Palliative (P) | 2013-11-01 | 2013-11-01 | LIPOSOMAL DOXORUBICIN | 2 | N | 320017063 | CARBO + FLUOROURACIL |
| 320002882 | 320001712 | 1.8 | null | Palliative (P) | 2017-08-02 | 2017-08-18 | CETUXIMAB + RT | N | N | 320017071 | CARBO + FLUOROURACIL |
| 320002883 | 320001713 | 1.5 | 62.2 | Palliative (P) | 2014-08-18 | 2014-08-26 | Cetuximab +Cisplatin + FU (Cycle 1) | 01 | N | 320017087 | IVADO |
| 320002884 | 320004898 | 1.69 | 127.2 | Palliative (P) | 2013-11-27 | 2013-12-20 | CETUXIMAB + RT | null | N | 320017094 | MITOMYCIN INTRAVESICULAR |
| 320002885 | 320001714 | null | 100.9 | Palliative (P) | 2016-06-20 | 2016-06-21 | Gemcitabine 1000mg/m2 D1 8 15 | N | N | 320017098 | IPILIMUMAB |
| 320002886 | 320001714 | 1.75 | 53.5 | Disease modification (D) | 2015-06-12 | 2015-06-20 | Carbo F | N | N | 320017098 | CISPLATIN + VINORELBINE |
| 320002887 | 320001715 | 1.59 | 105.9 | Curative (C) | 2014-05-08 | 2014-06-08 | VIDE | null | Y | 320017104 | CVP R |
| 320002888 | 320001716 | 1.52 | null | Curative (C) | 2017-06-04 | 2017-06-09 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 99 | Y | 320017105 | CETUXIMAB + RT |
| 320002889 | 320001717 | 1.69 | 66 | Curative (C) | 2015-06-16 | 2015-06-23 | EC | N | N | 320017115 | TRIAL |
| 320002890 | 320001718 | 1.55 | 33.2 | Curative (C) | 2014-01-01 | 2014-01-11 | CAPECITABINE + CARBOPLATIN + Cetuximab | 02 | Y | 320017116 | RITUXIMAB |